Caeser, Rebecca
Egger, Jacklynn V.
Chavan, Shweta http://orcid.org/0000-0001-9433-6936
Socci, Nicholas D.
Jones, Caitlin Byrne
Kombak, Faruk Erdem http://orcid.org/0000-0002-2781-7681
Asher, Marina
Roehrl, Michael H. http://orcid.org/0000-0003-4892-1098
Shah, Nisargbhai S.
Allaj, Viola
Manoj, Parvathy
Tischfield, Sam E. http://orcid.org/0000-0002-5717-3856
Kulick, Amanda
Meneses, Maximiliano http://orcid.org/0000-0002-4093-3070
Iacobuzio-Donahue, Christine A. http://orcid.org/0000-0002-4672-3023
Lai, W. Victoria
Bhanot, Umeshkumar http://orcid.org/0000-0001-6656-1239
Baine, Marina K.
Rekhtman, Natasha
Hollmann, Travis J. http://orcid.org/0000-0003-1599-0433
de Stanchina, Elisa
Poirier, John T. http://orcid.org/0000-0001-9795-5644
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Sen, Triparna
Article History
Received: 3 August 2021
Accepted: 28 March 2022
First Online: 19 April 2022
Competing interests
: C.M.R. has consulted regarding oncology drug development with Amgen, Daiichi Sankyo, Genentech/Roche, Ipsen, Jazz, Merck, Pfizer, Syros, and Vavotek. C.M.R. serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics. T.S. has research funding from Jazz Pharmaceuticals. The remaining authors declare no competing interests.